Russell Westbrook (Washington Wizards) with a 2-pointer vs the Sacramento Kings, 04/14/2021
Russell Westbrook (Washington Wizards) with a 2-pointer vs the Sacramento Kings, 04/14/2021
Cannabis irrigation system Cannabis irrigation system NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES TORONTO, May 06, 2021 (GLOBE NEWSWIRE) -- Water Ways Technologies Inc. (TSXV: WWT) ("Water Ways" or the "Company"), is pleased to announce that it received a CAD$130,000 new order for upgrading an existing Cannabis irrigation system to one of the largest Medical Cannabis licensed producers in Israel. Water Ways expects to deliver the system in Q3 of 2021. The order was comprised of the following components: Upgrading the existing irrigation system, redesigning and replacing all the electric valves and pipeline for water distribution to the different growing areas.The goals of the upgrade were to raise the level of uniformity in irrigation and fertilization to bring about a more uniform growth and yield.Design and installation of a system of water tanks allowing better control of the quality and quantity of water entering the irrigation system in the field.The system includes circulating the water in a UV system for water disinfection and continuous monitoring of the salinity (EC) and acidity (pH) levels in the water in order to pinpoint the amounts of fertilizer added to the irrigation water.Design and delivery of foggers cooling system, for the clones and vegetative growing rooms (VEG). The system is designed to decrease the temperature and enrich the space with moisture on hot and dry days.Design and installation of a reverse osmosis (RO) system and a dilution junction that can control the levels of salts in the water. The system will allow the introduction of salt-less water into the fogging system, and at the same time, the system is enabling to maintain constant levels of salts that reach the irrigation system. Ohad Haber, Chairman and Chief Executive Officer, commented: "We are gaining an excellent reputation in the Israeli medical cannabis market, one of the largest in the world, as the leading vendor of irrigation and fertilization solutions, due to our profound knowledge and experience in the technology of growing Cannabis precise tailor-made cultivation systems.” A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/d603ec0e-bce8-45fa-9b82-8190acb7ce06 About Water Ways Technologies Water Ways Technologies Inc., through its subsidiaries, is a global provider of Israeli-based agriculture technology, providing water irrigation solutions to agricultural producers. Water Ways Technologies competes in the global irrigation water systems market with a focus on developing solutions with commercial applications in the micro and precision irrigation segments of the overall market. At present, Water Ways Technologies' main revenue streams are derived from the following business units: (i) Projects Business Unit; and (ii) Component and Equipment Sales Unit. Water Ways Technologies is capitalizing on the opportunities presented by micro and smart irrigation, while also making a positive mark on society by making these technologies more widely available, especially in developing markets such as Africa and Latin America and developed markets such as China and Canada. Water Ways Technologies irrigation projects include vineyards, Cotton fields, Apple and Orange orchards, Blueberries, Medical Cannabis, fresh produce cooling rooms and more, in over 15 countries. For more information, please contact Ronnie JaegermannGuy NathanzonDirectorCFOT: +972-54-4202054T: +972-52-6007221E: email@example.comE: firstname.lastname@example.org https://www.water-ways-technologies.com/ Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. Forward-Looking Statements Certain statements contained in this press release constitute "forward-looking information" as such term is defined in applicable Canadian securities legislation. The words "may", "would", "could", "should", "potential", "will", "seek", "intend", "plan", "anticipate", "believe", "estimate", "expect" and similar expressions as they relate to Water Ways. All statements other than statements of historical fact may be forward-looking information. Such statements reflect Water Ways' current views and intentions with respect to future events, and current information available to Water Ways, and are subject to certain risks, uncertainties and assumptions. Material factors or assumptions were applied in providing forward-looking information. Many factors could cause the actual results, performance or achievements that may be expressed or implied by such forward-looking information to vary from those described herein should one or more of these risks or uncertainties materialize. Should any factor affect Water Ways in an unexpected manner, or should assumptions underlying the forward-looking information prove incorrect, the actual results or events may differ materially from the results or events predicted. Any such forward-looking information is expressly qualified in its entirety by this cautionary statement. Moreover, Water Ways does not assume responsibility for the accuracy or completeness of such forward-looking information. The forward-looking information included in this press release is made as of the date of this press release and Water Ways undertakes no obligation to publicly update or revise any forward-looking information, other than as required by applicable law. Water Ways' results and forward-looking information and calculations may be affected by fluctuations in exchange rates. All figures are in Canadian dollars unless otherwise indicated.
CN Rail (TSX:CNR)(NYSE:CNI) and Air Canada (TSX:AC) are top transportation plays that recently plunged, but are either worth a second look in May 2021? The post CN Rail or Air Canada: Which Stock Is the Better Buy on the Dip? appeared first on The Motley Fool Canada.
Global technology and power solutions leader Cummins Inc. (NYSE: CMI) and KBR (NYSE: KBR) have signed a memorandum of understanding (MoU) to collaborate on offering a complete and integrated solution to produce ammonia from renewable sources, commonly referred to as green ammonia. As leaders in their respective markets, Cummins in proton exchange membrane (PEM) electrolysis to generate hydrogen, and KBR with ammonia technologies, the companies have committed to explore the benefits of tightly integrated technologies that aim to provide significant capital and operational savings for their customers.
North American companies boosted spending on industrial robots in the first quarter as they scrambled to keep up with surging demand in the wake of the COVID-19 pandemic. Companies ordered 9,098 robots in the first quarter, a 19.6% increase over a year ago, according to the Association for Advancing Automation, an industry group based in Ann Arbor, Michigan. Robots were once concentrated in the auto industry but are now moving into more corners of the economy, from ecommerce warehouses to food processing plants.
Investing in RioCan could provide you with better rental-like income, as the proposed mortgage changes could lead to declining valuations. The post Housing Market: Will the Proposed Mortgage Change Slow Down the Housing Market? appeared first on The Motley Fool Canada.
The Wyoming Republican calls out members of her own party for following former President Trump's "cult of personality."
Global Next-Generation Ultrasound Systems Market to Reach $21. 08 Billion by 2031. Market Report Coverage - Next Generation Ultrasound Systems Market Segmentation.New York, May 06, 2021 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global Next Generation Ultrasound Systems Market: Focus on Product Type, Technology, and Application, Portability, End User, and Region (14 Countries) - Analysis and Forecast, 2021-2031" - https://www.reportlinker.com/p06067444/?utm_source=GNW • Technology – 2D Ultrasound Systems, 4D/3D Ultrasound Systems, and Others (Fusion Imaging, Tissue Harmonic Imaging)• Product Type – Diagnostic Ultrasound Systems, and Therapeutic Ultrasound Systems• Portability – Cart/Trolley-Based Systems, Portable Systems, and Handheld Devices and Wearables• Application – General Imaging, Cardiology Imaging, Vascular Imaging, Obstetrics and Gynecology Imaging, Lung Imaging, Urology, Orthopedics/Musculoskeletal Imaging, and Other Imaging• End User – Hospitals, Diagnostic Centers, Ambulatory Surgical Centers (ASCs), and OthersRegional Segmentation• North America- U.S. and Canada• Europe- Germany, U.K., Italy, Spain, France, Switzerland, Sweden, and Rest-of-Europe• Asia-Pacific- Japan, China, South Korea, Australia and New Zealand, India, and Rest-of-Asia-Pacific• Latin America• Middle East and AfricaGrowth Drivers• Advent of Point-of-Care Ultrasound Systems Driving a Fast-Paced Growth• Integration of Artificial Intelligence into Ultrasound• Rising Need for Examination in Case of Increasing Prevalence of Chronic DiseasesMarket Restraints• Limitations with Resolution and Quality of Images• Product Recall and Shortage of Trained Technicians• Growing End User Preference for Refurbished EquipmentMarket Opportunities• Advancement in Technology Promising a Strong Growth Potential• Improving Ultrasound WorkflowKey Companies ProfiledBK Medical ApS (Analogic Corporation), Butterfly Network Inc., Canon Inc., Clarius Mobile Health, Esaote SpA, Fujifilm Holdings Corporation, General Electric Company, Healcerion Co. Ltd., Hitachi Ltd., Hologic Inc., Koninklijke Philips N.V., Samsung Electronics Co. Ltd., Shenzhen Mindray Bio-Medical Electronics Co. Ltd., Shimadzu Corporation, and Siemens Healthineers AGKey Questions Answered in this Report:• What is the current scenario of global next-generation ultrasound systems market?• What is the total market size and forecast (until 2031) for the global next-generation ultrasound systems market?• What is the addressable market size and forecast based on region?• What are the key market dynamics (drivers, restraints, trends, and opportunities) for the global next-generation ultrasound systems market?• What is the impact of different macroeconomic factors on the dynamics of the global next-generation ultrasound systems market?• How would trends impacting the dynamics of the market evolve during the forecast period?• What are the hidden factors that are driving the global next-generation ultrasound systems market through the iceberg analysis? • What are the key strategies incorporated by the leading players of the global next-generation ultrasound systems market to sustain the competition?• What are the market shares of key competitors in the global next-generation ultrasound systems market?• What will be the revenue growth rate witnessed by each key player in the forecast period?• What is the scale of impact on the dynamics of the market due to strategic decisions made by leading players in the market?• What has been the funding scenario for the next-generation ultrasound systems from the past four years? • What are the average selling prices of the next-generation ultrasound systems?• What are the regulations impacting the global next-generation ultrasound systems market across different regions?• What are the business models of key competitors in the global next-generation ultrasound systems market? • What is the current brand value of key competitors in the global next-generation ultrasound systems market?• What is the current total market size and forecast for different application categories available in the global next-generation ultrasound systems market?• What are the current trends associated with each application categories?• Which application category is anticipated to witness the highest growth rate during the forecast period?• What is the current total market size and forecast for the global next-generation ultrasound systems market across different regions?• What are the forward-looking trends associated with each region?• What is the role of each company in the global next-generation ultrasound systems market?• What is the revenue generated through the sales of next-generation ultrasound systems by each company?• What are strengths, weaknesses, opportunities, and threats for each company in the global next-generation ultrasound systems market?Overview on the Global Next-Generation Ultrasound Systems MarketGlobal next-generation ultrasound systems market is currently witnessing a significant change in the market landscape.There is rising investment in the development of healthcare infrastructure, increasing evidence for efficient and promising results in treatment and diagnosis assistance.Moreover, there is an extensive entry of emerging players developing advanced ultrasound systems into the healthcare space. All these predominant factors have led to a significant rise in sales of ultrasound systems across the globe.Global Next-Generation Ultrasound Systems Market ForecastThe global next-generation ultrasound systems market was valued at $8,246.8 million in 2020 and is anticipated to reach $21,079.7 million by 2031, growing at a CAGR of 9.3% during the forecast period 2021-2031. The increasing demand for quality ultrasound systems for the medical field, availability of technologically advanced products in the field of 3D, 4D, and upcoming 5D ultrasound systems, the increasing incidences of targeted diseases, and government funding and R&D investments during COVID-19, are the major factors fueling the market growth. In addition to these factors, there are significant challenges and restraints, which are restricting the market growth. These challenges include the limitations of ultrasound systems, product recalls, shortage of trained technicians, growing end user preference for refurbished ultrasound systems, etc. Hence, it is anticipated that these factors will have a significant impact on the ultrasound systems market in the next five years, and the market will grow multifold.Competitive LandscapeThe global next-generation ultrasound systems market consists of numerous large-scale as well as small-scale manufacturers and vendors. Presently, the manufacturers in the market have ample opportunities to expand their offerings and to establish a strong foothold in the market.During January 2017 - March 2021, the market witnessed approximately 48 joint ventures, collaborations, and partnerships, three funding and investments, 16 product approvals, 28 product launches and enhancements, and one merger and acquisition. Joint ventures, collaborations, and partnerships were among the most frequently followed strategies that were incorporated by numerous players to establish a strong foothold in the market.Most of the manufacturers in the market are incorporating collaborations and partnerships not only with other companies but also the university and research institutions as the key strategies to develop next-generation ultrasound systems and attain a strong financial position in the market.Moreover, the leading players in the global next-generation ultrasound systems market include BK Medical ApS (Analogic Corporation), Butterfly Network Inc., Canon Inc., Clarius Mobile Health, Esaote SpA, Fujifilm Holdings Corporation, General Electric Company, Healcerion Co. Ltd., Hitachi Ltd., Hologic Inc., Koninklijke Philips N.V., Samsung Electronics Co. Ltd., Shenzhen Mindray Bio-Medical Electronics Co. Ltd., Shimadzu Corporation, and Siemens Healthineers AG, among others.Countries Covered• North America• U.S.• Canada• Europe• Germany• Italy• France• Spain• U.K.• Switzerland• Sweden• Rest-of-Europe• Asia-Pacific• China• India• Japan• South Korea• Australia and New Zealand (ANZ)• Rest-of-Asia-Pacific• Latin America• Middle East and AfricaRead the full report: https://www.reportlinker.com/p06067444/?utm_source=GNWAbout ReportlinkerReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.__________________________ CONTACT: Clare: email@example.com US: (339)-368-6001 Intl: +1 339-368-6001
Support staff travelling to Tokyo will also have access to the jab.
A top official in South Africa's African National Congress (ANC) has appealed against his suspension on corruption charges and attempted to suspend President Cyril Ramaphosa in an increasingly open power struggle in the governing party. ANC Secretary General Ace Magashule, who has denied the corruption allegations, was suspended on Wednesday by the party once led by late apartheid fighter Nelson Mandela. The move follows an anti-corruption campaign launched by Ramaphosa in 2018 when he took over as state president with promises to crack down hard on widespread graft.
Q2 Holdings Inc. (NYSE: QTWO), a leading provider of digital transformation solutions for banking and lending, today released its first Environmental, Social and Governance (ESG) report. The report highlights how the company is addressing the top ESG priorities that matter to its employees, customers, partners, and other stakeholders.
–In collaboration, Aeterna and The University of Sheffield, UK have selected the development candidate AEZS-150, a parathyroid hormone (PTH) fusion polypeptide to start the formal preclinical development for potentially enabling the first in human clinical study. –AEZS-150 has the potential to become a new therapeutic treatment option of primary hypoparathyroidism. CHARLESTON, S.C., May 06, 2021 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) through its wholly-owned subsidiary Aeterna Zentaris GmbH, (“Aeterna” or the “Company”), a specialty biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products, today announced that, in consultation with The University of Sheffield, UK (the “University”), Aeterna has selected AEZS-150 as the lead candidate in the Company’s delayed clearance parathyroid hormone fusion polypeptides (DC-PTH) program. Aeterna will now start the formal preclinical development of AEZS-150 in preparation for a potential IND filing for conducting the first in-human clinical study of AEZS-150. AEZS-150 is being developed with the goal of providing a potential new treatment option of primary hypoparathyroidism in adults. “We are very excited to have identified AEZS-150 as the development candidate within our DC-PTH program. We are in contact with CMOs to establish the GMP manufacturing process to prepare material for the required toxicology and safety assessment of AEZS-150. At this point in time the Aeterna team with its proven expertise can contribute on the formal development process of a new chemical entity (NCE). We look forward to continuing and advancing the development of our collaboration with the University and Prof. Dr. Ross. We are now a step closer towards our common goal of potentially helping patients suffering from hypoparathyroidism,” commented Dr. Klaus Paulini, Chief Executive Officer of Aeterna. AEZS-150 is a DC-PTH consisting of a modified growth hormone binding protein (GHBP) linked to PTH1-34. It is being developed with the goal of producing a product with delayed clearance of one or two weeks and the potential to be self-administered via a pharmaceutical pen. If successful, it would help patients maintain normal serum calcium and phosphate levels during chronic use. The technology is based on proprietary intellectual property exclusively licensed by Aeterna from the University. Prof. Dr. Richard J. Ross of the University added, “We are very optimistic about the development candidate AEZS-150 and the start of the preclinical program. We will now focus on the further characterization of AEZS-150 in disease specific in-vitro and in-vivo models. We are confident that Aeterna is the right partner to pursue the manufacturing process and the formal preclinical development.” Primary hypoparathyroidism, the first indication for candidate AEZS-150, is an orphan indication in the field of endocrinology. It is an uncommon condition in which the body produces abnormally low levels of PTH. PTH is a key regulating hormone essential for calcium homeostasis and renal phosphate clearance for maintaining a balance of those two minerals in the body. Untreated, primary hypoparathyroidism will cause, among other effects, renal dysfunction, muscle cramping, twitching, seizures, and cardiac arrhythmias. Approximately 23 to 37 in every 100,000 individuals in Europe and the U.S. are estimated to suffer from hypoparathyroidism. About Aeterna Zentaris Inc. Aeterna Zentaris is a specialty biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products focused on areas of significant unmet medical need. The Company’s lead product, macimorelin, is the first and only U.S. FDA and European Commission approved oral test indicated for the diagnosis of adult growth hormone deficiency (AGHD). The Company is leveraging the clinical success and compelling safety profile of macimorelin to develop it for the diagnosis of childhood-onset growth hormone deficiency (CGHD) in collaboration with Novo Nordisk.Aeterna Zentaris is dedicated to the development of therapeutic assets and has recently taken steps to establish a growing pipeline to address unmet medical needs across a number of indications, including neuromyelitis optica spectrum disorder (NMOSD), primary hypoparathyroidism and neurodegenerative disease. Additionally, the Company is developing an oral prophylactic bacterial vaccine against SARS-CoV-2, the virus that causes COVID-19. For more information, please visit www.zentaris.com and connect with the Company on Twitter, LinkedIn and Facebook. Forward-Looking Statements This press release contains forward-looking statements (as defined by applicable securities legislation) made pursuant to the safe-harbor provision of the U.S. Securities Litigation Reform Act of 1995, which reflect our current expectations regarding future events. Forward-looking statements in this press release include those relating to the development of AEZS-150 as a potential new therapeutic treatment option for primary hypoparathyroidism and the effect and method of administration of any product developed with AEZS-150. Forward-looking statements involve known and unknown risks and uncertainties, including those discussed in this press release and in our Annual Report on Form 40-F, under the caption "Key Information - Risk Factors" filed with the relevant Canadian securities regulatory authorities in lieu of an annual information form and with the U.S. Securities and Exchange Commission. Known and unknown risks and uncertainties could cause our actual results to differ materially from those in forward-looking statements. Such risks and uncertainties include, among others, results from ongoing or planned pre-clinical and clinical studies of our other products under development may not be successful; our ability to raise capital and obtain financing to continue our currently planned operations, our ability to continue to list our Common Shares on the NASDAQ; our now heavy dependence on the success of Macrilen™ (macimorelin) and related out-licensing arrangements and the continued availability of funds and resources to successfully commercialize the product, including our heavy reliance on the success of the License Agreements for macimorelin; the global instability due to the global pandemic of COVID-19, and its unknown potential effect on our planned operations; our ability to enter into out-licensing, development, manufacturing, marketing and distribution agreements with other pharmaceutical companies and keep such agreements in effect; our ability to enter into out-licensing, development, manufacturing, marketing and distribution agreements with other pharmaceutical companies and keep such agreements in effect; our reliance on third parties for the manufacturing and commercialization of Macrilen™ (macimorelin), potential disputes with third parties, leading to delays in or termination of the manufacturing, development, out-licensing or commercialization of our product candidates, or resulting in significant litigation or arbitration, uncertainties related to the regulatory process; our ability to efficiently commercialize or out-license Macrilen™ (macimorelin), our reliance on the success of the pediatric clinical trial in the European Union (“E.U.”) and U.S. for Macrilen™ (macimorelin), the degree of market acceptance of Macrilen™ (macimorelin), our ability to obtain necessary approvals from the relevant regulatory authorities to enable us to use the desired brand names for our product, our ability to successfully negotiate pricing and reimbursement in key markets in the E.U. for Macrilen™ (macimorelin), our ability to protect our intellectual property, and the potential of liability arising from shareholder lawsuits and general changes in economic conditions. Investors should consult our quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties. Given these uncertainties and risk factors, readers are cautioned not to place undue reliance on these forward-looking statements. We disclaim any obligation to update any such factors or to publicly announce any revisions to any of the forward-looking statements contained herein to reflect future results, events or developments, unless required to do so by a governmental authority or applicable law. Investor Contact: Jenene ThomasJTC TeamT (US): +1 (833) 475-8247E: firstname.lastname@example.org
Marty Young presents on creating TPA-in-a-box at CB Insights Tech Market: Digitizing P&C Insurance, taking place virtually on May 13-14, 2021
TAMPA, Fla., May 06, 2021 (GLOBE NEWSWIRE) -- LM Funding America, Inc. (NASDAQ:LMFA) ("LM Funding" or "LMFA"), a technology-based specialty finance company, today announced a 1-for-5 reverse stock split of its outstanding common stock, effective at 12:01 a.m. Eastern time on May 7, 2021. Beginning tomorrow, May 7, 2021, LM Funding’s common stock will trade on a split-adjusted basis. At LM Funding’s Annual Meeting of Shareholders (the “Annual Meeting”) held on May 11, 2020, the Company’s shareholders approved a proposal to amend the Company’s Certificate of Incorporation to effect a reverse stock split of its common stock at a ratio within the range of one-for-two (1:2) to one-for-ten (1:10), as determined by the Company’s Board of Directors. On April 21, 2021, the Board of Directors approved a 1-for-5 reverse split, and on May 5, 2021, LM Funding filed a Certificate of Amendment to its Certificate of Incorporation to effect the reverse stock split effective as of May 7, 2021. “Consistent with the reason for obtaining shareholder approval of the reverse split proposal at our most recent annual shareholder meeting,” said Bruce M. Rodgers, Chairman and CEO of LM Funding, “our Board of Directors believe that it is our shareholders’ best interest to raise the per-share trading price of our common stock to ensure continued compliance with Nasdaq’s $1.00 minimum bid price requirement and to make our stock more attractive to a broader range of institutional and other investors.” Mr. Rodgers added: “The reverse stock split will also effectively make available an increased number of authorized but unissued shares to pursue potential acquisitions, additional financing activities, and/or other strategic transactions to grow shareholder value in the wake of our substantially improved cash position, our sponsorship of a successful SPAC IPO in January 2021, and the launch of our recently announced digital assets strategy.” LM Funding’s shares of common stock will continue to trade on the NASDAQ under the symbol “LMFA.” The new CUSIP number for the Company’s common stock post reverse stock split is 502074404. Upon the effectiveness of the reverse stock split, every 5 shares of LM Funding’s issued and outstanding common stock will automatically be converted into one share of common stock. No fractional shares will be issued if, as a result of the reverse stock split, a stockholder would otherwise become entitled to a fractional share. Instead, each stockholder will be entitled to receive a cash payment equal to the product of the closing price of the Company’s common stock on May 6, 2021 and the amount of the fractional share. About LM Funding America:LM Funding America, Inc., together with its subsidiaries, is a technology-based specialty finance company that provides funding to nonprofit community associations (Associations) primarily located in the state of Florida, as well as in the states of Washington, Colorado and Illinois, by funding a certain portion of the associations' rights to delinquent accounts that are selected by the Associations arising from unpaid Association assessments. Forward-Looking Statements: This press release may contain forward-looking statements made pursuant to the Private Securities Litigation Reform Act of 1995. Words such as “anticipate,” “believe,” “estimate,” “expect,” “intend,” “plan,” and “project” and other similar words and expressions are intended to signify forward-looking statements. Forward-looking statements are not guaranties of future results and conditions but rather are subject to various risks and uncertainties. Some of these risks and uncertainties are identified in the company's most recent Annual Report on Form 10-K and its other filings with the SEC, which are available at www.sec.gov. These risks and uncertainties include, without limitation, uncertainty created by the COVID-19 pandemic, our ability to acquire new accounts in our specialty finance business at appropriate prices, the need for capital, our ability to hire and retain new employees, changes in governmental regulations that affect our ability to collected sufficient amounts on defaulted consumer receivables, changes in the credit or capital markets, changes in interest rates, and negative press regarding the debt collection industry. The occurrence of any of these risks and uncertainties could have a material adverse effect on our business, financial condition, and results of operations. Company Contact:Bruce M. Rodgers, Chairman and CEOLM Funding America, Inc.Tel (813) email@example.com
QYOU Media Inc. (TSXV: QYOU) (OTCQB: QYOUF) has announced that The Q India, the company's Hindi language youth oriented channel available in over 100 million TV households and to over 612 million OTT and mobile users in India, has reported the addition of Amazon, the world's largest online marketplace and the largest internet company by revenue in the world, as a new advertiser on The Q India. Amazon joins previously announced premium advertisers including Pepsi, Unilever and Wipro as The Q India solidifies its ratings and viewership metrics across the board.
U.S. cybersecurity services firm adds NBA executive as directorSCOTTSDALE, Ariz., May 06, 2021 (GLOBE NEWSWIRE) -- Cerberus Cyber Sentinel Corporation (OTC: CISO) (“Cerberus Sentinel”), a cybersecurity consulting and managed services firm, announced today that E.M. "Kiki" VanDeWeghe III has been appointed to its board of directors. VanDeWeghe adds significant executive and management experience to Cerberus Sentinel’s board of directors. Currently, VanDeWeghe serves as executive vice president, basketball operations, for the National Basketball Association. In this role, he oversees all aspects of basketball related to the playing of the game, and he serves as a key liaison between the league office and its teams. He was a two-time NBA All-Star during his 13-year playing career, and he has previously served as general manager with the Denver Nuggets and New Jersey Nets. VanDeWeghe played collegiately at UCLA and was a Rhodes Scholar finalist. “Kiki VanDeWeghe is an outstanding addition to our board,” said David Jemmett, founder and CEO of Cerberus Sentinel. “His experience within the NBA gives him a unique perspective of the operations and security challenges of multi-national organizations and vendor networks.” “Each of our board members provides a unique perspective to the company, including government, healthcare, and finance expertise,” said Jemmett. “Mr. VanDeWeghe raises our national and international experience and brings his exceptional expertise to our board.” “It is a great honor to be joining the board of Cerberus. I look forward to collaborating with the many bright minds entrusted with helping shape the future and vision of the company as we move forward in a very important space,” said VanDeWeghe. VanDeWeghe joins fellow board members Ret. Gen. Robert Oaks, Scott Holbrook, Andrew McCain, Sandra Morgan, Stephen Scott, and David Jemmett. About Cerberus Sentinel Cerberus Sentinel is an industry leader in Managed Cybersecurity and Compliance (MCCP) services with its exclusive MCCP+ managed cybersecurity and compliance services plus culture program. The company seeks to expand by acquiring world-class cybersecurity talent and utilizes the latest technology to create innovative solutions that protect the most demanding businesses and government organizations against continuing and emerging security threats. Safe Harbor Statement This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements including words such as "believes," "expects," "anticipates," "intends," "estimates," "plan," "will," "may," "look forward," "intend," "guidance," "future" or similar expressions are forward-looking statements. Because these statements reflect Cerberus Sentinel's current views, expectations and beliefs concerning future events, these forward-looking statements involve risks and uncertainties. Investors should note that many factors, as more fully described under the caption "Risk Factors" and elsewhere in Cerberus Sentinel's Form 10-K, Form 10-Q and Form 8-K filings with the Securities and Exchange Commission and as otherwise enumerated herein, could affect Cerberus Sentinel's future financial results and could cause actual results to differ materially from those expressed in such forward-looking statements. The forward-looking statements in this press release are qualified by these risk factors. These are factors that, individually or in the aggregate, could cause the Cerberus Sentinel's actual results to differ materially from expected and historical results. You should not place undue reliance on any forward-looking statements, which speak only as of the date they are made. We assume no obligation to publicly update any forward-looking statements, whether as a result of new information, future developments or otherwise. Investor Relations:Matt Glover or Alex KovtunGateway Investor Relations949-574-3860CISO@gatewayir.com Public Relations:Cathy Morley FosterEskenzi PR925firstname.lastname@example.org
Charles River Associates (NASDAQ: CRAI), a worldwide leader in providing economic, financial and management consulting services, today announced financial results for the fiscal first quarter ended April 3, 2021.
One woman suffered a ‘colossal interference’ with her right to family life because of fees the Home Office charged.
Oculii, a startup that makes software to boost the resolution of radars for use in self-driving cars, said on Thursday it raised $55 million in its latest funding round. Radars are already widely used in cars to assist with emergency braking, blindspot detection, and parking-assist systems, but the low resolution of the image limits its usage, said Steven Hong, CEO of the Dayton, Ohio startup. The artificial intelligence software Oculii has developed can boost the radar resolution by 100 times, Hong said.
LONDON — France dispatched two patrol boats Thursday as French fishermen angry over loss of access to waters off their coast gathered for a maritime protest off the English Channel island of Jersey, the flashpoint for the first major dispute between France and Britain over fishing rights in the wake of Brexit. The naval policing boats Athos and Themis were sent to keep watch on waters between France and Jersey, French maritime authorities for the English Channel and North Sea said. The deployment came after Britain on Wednesday directed two Royal Navy vessels, HMS Severn and HMS Tamar, to also patrol the waters around the island, a self-governing British Crown Dependency near the coast of northern France. French fishermen have steamed into Jersey waters to demonstrate against new rules requiring them to submit their past fishing activities in order to receive a license to continue operating in the island's waters. Dimitri Rogoff, who heads a grouping of fishermen, said about 50 boats from French ports along the western Normandy coast joined the protest Thursday morning, gathering their fleet off the Jersey port of St. Helier. He said the protest over licenses for French fishermen was not an attempt to blockade the port but rather a peaceful method of voicing anger over reduced access to Jersey waters. “This isn't an act of war,” Rogoff said in a phone interview. “It's an act of protest.” French authorities said their vessels were there to assist in any maritime emergencies. “We would thus be capable of intervening rapidly should the situation worsen, which is not the case at the moment,” they said in an emailed statement to The Associated Press. The British government said its Royal Navy vessels were there to “monitor the situation." Opponents accused Prime Minister Boris Johnson of escalating the crisis, and of using the fishing spat as an Election Day stunt. The story dominated newspaper front page on Thursday, as voters go to the polls in local and regional elections in England, Scotland and Wales. But the move was welcomed by Jersey fishermen. Fisherman John Dearing said the scene off St. Helier on Thursday was “like an invasion." “It was quite a sight,” he told British news agency PA. “It was impressive, I looked from the shore this morning and it was just like a sea of red lights and flares already going off at sea.” There have been numerous bouts of friction in the past between French and U.K. fisherman. The latest dispute, the first since Britain’s departure from the European Union, came after the island implemented new requirements that make fishermen account for their past work in Jersey waters to be eligible for a license to continue operating there. Authorities on Jersey, the largest of the Channel Islands, have accused France of acting disproportionately after Paris threatened to cut off electricity to the island. Jersey and the other Channel Islands are closer to France than to Britain. Jersey receives most of its electricity from France, supplied through undersea cables. French maritime minister Annick Girardin warned Tuesday that France was ready to take “retaliatory measures,” accusing Jersey of stalling in issuing licenses to French boats under the terms of the U.K.’s post-Brexit trade deal with the EU. Economically insignificant but culturally important, fishing was the thorniest issue in U.K.-EU divorce talks, and the last to be settled. Under post-Brexit rules that took effect May 1, French boats need permits from the Jersey government to fish in the island’s waters. The French say there have been holdups in issuing some of the licenses, and the permits come with unexpected restrictions that could drive many out of business. Jill Lawless And John Leicester, The Associated Press
VersusGame x Consumable Release